We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sistemic Announces Companion Biomarker Program
Product News

Sistemic Announces Companion Biomarker Program

Sistemic Announces Companion Biomarker Program
Product News

Sistemic Announces Companion Biomarker Program


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Sistemic Announces Companion Biomarker Program"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sistemic, has announced the release of it’s new Companion Biomarker program. Extending the company’s existing SistemRNA™ suite of drug discovery and development tools, the Companion Biomarker program simplifies the benefits of miRNA analysis and profiling to support timely decision making within clinical research.

Drug discovery companies will be able to utilize new multiple miRNA biomarkers to determine the efficacy of targeted drugs, in major therapeutic areas and when developing companion biomarker strategies for future clinical development.

MicroRNA profiling has rapidly become an indispensable technology with a whole catalogue of applications and new opportunities.

Companion biomarkers are the most recent extension of the technology and are set to provide valuable clinical data to guide both pre-clinical and clinical studies.

The system will use the robustness and specificity of miRNA to identify highly discriminatory biomarkers which, in turn, will guide patient prognosis, the selection of appropriate drug treatment, and monitoring of drug response.

Advertisement